Anzeige
Mehr »
Samstag, 07.06.2025 - Börsentäglich über 12.000 News
Starke Zahlen: EBITDA bei 9 Mio.?€ - Startet jetzt die Neubewertung?
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A2P200 | ISIN: KYG0146B1032 | Ticker-Symbol: 4RY
Stuttgart
06.06.25 | 08:10
8,900 Euro
0,00 % 0,000
Branche
Biotechnologie
Aktienmarkt
ASIEN
1-Jahres-Chart
AKESO INC Chart 1 Jahr
5-Tage-Chart
AKESO INC 5-Tage-Chart
RealtimeGeldBriefZeit
9,0009,40006.06.
9,1009,40006.06.

Aktuelle News zur AKESO Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
DoAkeso gains NMPA approval for cadonilimab to treat cervical cancer1
DoAkeso's Cadonilimab Gets NMPA Approval For First-line Cervical Cancer Treatment1
DoAKESO (09926): VOLUNTARY ANNOUNCEMENT - NMPA APPROVED THE SNDA FOR CADONILIMAB (PD-1/CTLA-4) AS FIRST-LINE TREATMENT FOR CERVICAL CANCER2
MiJPMorgan senkt Kursziel für Akeso wegen US-Regulierungsbedenken4
MiJPMorgan lowers Akeso stock price target due to US regulatory concerns2
MoJefferies: HARMONi Trial Confirms CN Data Credibility; AKESO (09926.HK) TP $1504
30.05.Akeso, Summit's ivonescimab delayed progression by 48% in certain lung cancers in first global phase 3 readout9
26.05.AKESO (09926): GRANT OF SHARE OPTIONS AND RESTRICTED SHARE UNITS1
AKESO Aktie jetzt für 0€ handeln
14.05.DelveInsight Business Research, LLP: Akeso's Penpulimab Approval Intensifies the Competition Among the Other Pharmaceutical Companies Active in the Nasopharyngeal Carcinoma Market | DelveInsight523The FDA has approved Akeso's PD-1 monoclonal antibody, penpulimab-kcqx, for the treatment of recurrent or metastatic non-keratinising nasopharyngeal carcinoma in adults. The approval includes...
► Artikel lesen
29.04.AKESO (09926): NOTIFICATION LETTER AND REPLY FORM TO NON-REGISTERED HOLDERS - REMINDER LETTER REGARDING THE ARRANGEMENT OF ELECTRONIC DISSEMINATION OF ...-
29.04.AKESO (09926): NOTIFICATION LETTER AND REPLY FORM TO REGISTERED SHAREHOLDERS - REMINDER LETTER REGARDING THE ARRANGEMENT OF ELECTRONIC DISSEMINATION OF ...-
29.04.AKESO (09926): 2024 ENVIRONMENTAL, SOCIAL AND GOVERNANCE REPORT-
29.04.AKESO (09926): 2024 ANNUAL REPORT3
28.04.New Akeso, Summit data stir debate on PD-1/VEGF drugs4
28.04.'Deviated from core': Akeso CEO tries to reset expectations of bispecific's survival readout amid market tumult4
25.04.Summit stock crashes as Akeso shares bispecific's first overall survival data in Keytruda head-to-head trial3
25.04.Akeso, Sino Biopharm's Anniko enters crowded PD-1 market with FDA approval in head and neck cancer subtype12
25.04.FDA approves Akeso's monoclonal antibody for nasopharyngeal carcinoma5
25.04.Akeso PD-1 inhibitor cleared as Keytruda challenger advances4
25.04.FDA Approves Akeso's Penpulimab for Nasopharyngeal Carcinoma3
Weiter >>
52 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,3